Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Patients with severe COVID-19 often suffer from significant pulmonary fibrosis. Although the pathogenesis of pulmonary fibrosis has not been fully explained, the signal pathways and cytokines involved are very similar to hepatic fibrosis. This has been successfully treated with t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Chi Zhang, Jiawen Li, Zhao Wu, He Wang, Chengli Que, Hong Zhao, Guiqiang Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2020-06-01
Edice:	Trials
Témata:	COVID-19 Randomised controlled trial Protocol Pulmonary fibrosis Anluohuaxian
On-line přístup:	http://link.springer.com/article/10.1186/s13063-020-04399-8
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!